Impact of Pre-operative Bevacizumab on Complications After Resection of Colorectal Liver Metastases

Sponsor
University of Zurich
Study ID
NCT00875147
Status
Completed

Conditions

  • Colorectal Liver Metastases

Eligibility Criteria

Sex
ALL
Age
18 Years - 90 Years
Healthy Volunteers
Not accepted

Interventions

  • bevacizumab — DRUG
    Neoadjuvant chemotherapy with bevacizumab

Study Details

Hypothesis of the study: Neoadjuvant chemotherapy with Bevacizumab impairs postoperative outcome after resection of colorectal liver metastases.

Key Dates

First listed
Apr 3, 2009
Start date
Apr 30, 2009
Status verified
Jan 2010
Primary completion
Aug 31, 2009
Completion
Sep 30, 2009

Study Design

Enrollment
163 participants (actual)

Arms

  • Arm: with bevacizumab
    Neoadjuvant chemotherapy with bevacizumab
  • Arm: without Bevacizumab
    Neoadjuvant chemotherapy without Bevacizumab

Primary Outcome Measure

Overall complications [ Time Frame: postoperative ]

Related Studies